12.03.2024 - Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate . Seite 1
25.09.2023 - SHANGHAI, China, Sept. 25, 2023 (GLOBE NEWSWIRE) - NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”) is a pioneer and a leading company in the premium smart electric vehicle market. The Company has been made aware of certain . Seite 1
20.09.2023 - SHANGHAI, China, Sept. 19, 2023 (GLOBE NEWSWIRE) - NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced the pricing of US$500 million in . Seite 1
16.08.2023 - SHANGHAI, China, Aug. 16, 2023 (GLOBE NEWSWIRE) - NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced that it will report its second .
INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.